Target- |
MechanismDNA synthesis inhibitors |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.FR |
First Approval Date01 Jan 1960 |
|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.JP |
First Approval Date11 Oct 1954 |
|
|
|
|
|
|
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Randomised, Double-blind, Placebo-controlled Trial Evaluating the Effects of Metronidazole Ointment in Facilitating Resolution of Non-healing Pilonidal Sinus Wounds.
Title of Study:
Randomised, double-blind, placebo-controlled trial evaluating the effects of metronidazole ointment in facilitating resolution on non-healing pilonidal sinus wounds Medical Condition Under Investigation Non-healing pilonidal sinus wounds
Study centres: 2 Centres in Turkey
Clinical Phase: Phase 2
Protocol Number: MET-PS-02
Study Design: Randomised, double-blind, placebo-controlled, parallel group study to determine the safety and efficacy of metronidazole ointment applied to the wound, following debridement in non-healing pilonidal sinus wounds.
Planned Sample Size: 80 subjects
A Randomised, Double-blind, Placebo Controlled Study of Eicosapentaenoic Acid (EPA-FFA) Gastro-resistant Capsules to Treat Hospitalised Subjects With Confirmed SARS-CoV-2
This is an double-blind, randomized, placebo controlled phase III study in hospitalized subjects with confirmed SARS-CoV-2.
/ Active, not recruitingPhase 3 Randomised, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Tolerability of EPA-FFA Gastro-resistant Capsules, in Patients With Familial Adenomatous Polyposis (FAP)
2 Year randomised, double-blind, placebo-controlled, parallel group study to determine the safety and efficacy of EPA-FFA gastro resistant capsules in FAP.
100 Clinical Results associated with S.L.A. Pharma AG
0 Patents (Medical) associated with S.L.A. Pharma AG
100 Deals associated with S.L.A. Pharma AG
100 Translational Medicine associated with S.L.A. Pharma AG